Date: 2013-03-19
Type of information: Grant
Company: Addex Therapeutics (Switzerland)
Investors: The Michael J. Fox Foundation - MJFF (USA)
Amount: $ 1 million (€ 0.77 million)
Funding type: grant
Planned used: This grant will help fund continued human clinical testing of dipraglurant for the treatment of Parkinson\'s disease levodopa-induced dyskinesia (PD-LID).
Others: * On March 19, 2013, Addex Therapeutics, a company pioneering allosteric modulation-based drug discovery and development, and The Michael J. Fox Foundation for Parkinson\'s Research announced that the Foundation awarded a $1,000,000 grant to Addex to help fund continued human clinical testing of dipraglurant for the treatment of Parkinson\'s disease levodopa-induced dyskinesia (PD-LID).
Dipraglurant is an oral, small molecule allosteric modulator that inhibits selectively the metabotropic glutamate receptor 5 (mGluR5), a Class C G-Protein Coupled Receptor (GPCR). The Michael J. Fox Foundation has invested more than $26 million in dyskinesia-targeted research to date, including support for a successful Phase 2a trial of dipraglurant completed by Addex in 2012. Data from this Phase 2a study showed that dipraglurant met the primary objective by exhibiting a good safety and tolerability profile. Dipraglurant also demonstrated a statistically significant reduction in LID severity with both 50 and 100 mg doses. Dipraglurant appears to reduce dystonia severity in addition to chorea, the two major LID components.
Therapeutic area: Neurodegenerative diseases
